Vidostream | News, sport and opinion from the Vidostream's US Edition

https://vidostream.com

Novavax says its COVID-19 vaccine is 90% effective

Unlike the Pfizer vaccine, Novavax’s version does not need special refrigeration, making it easier to distribute.

Novavax, a Maryland-based biotech company, announced Monday that its COVID-19 vaccine is 90.4% effective at preventing people from getting sick and 100% effective at preventing moderate or severe disease, hopefully laying the groundwork for a fourth vaccine in the fight against the coronavirus.

Nearly 30,000 participants across 119 sites in the U.S. and Mexico took part in the Phase 3 study, which evaluated “efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.”

Of those who got the two-shot inoculation, only 77 people tested positive for COVID-19, and all cases were “mild.” No hospitalizations or deaths were reported.

Among high-risk populations — those over age 65, under age 65 with certain comorbidities or having life circumstances with frequent COVID-19 exposure — the Novavax vaccine was 91% effective, the company said.

“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax President and CEO Stanley Erck said in a statement.

“Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines.”

Read More (...)

Source: NY Daily News:

We are using cookies to give you the best experience on our website. By continuing to browse, you are agreeing to our Cookie Policy.
You did not use the site, Click here to remain logged. Timeout: 60 second